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Abstract

Introduction: Canine Malignant Melanoma (CMM) is a very aggressive, potential metastatic neoplasm of melanocytes. They account for 9 to 20% of all skin tumors and occur in dogs that have heavily pigmented skin or oral mucosa. CMM have a high chance of metastasis (51%) even after surgical removal of the primary tumor and adjuvant therapy. The mean survival time for dogs with CMM is 5 to 8 months. Xenogeneic DNA vaccination of dogs with CMM induce an immune response and may increase the survival time significantly. 
Aim of study: The aim of this study was to investigate the effectiveness of the CMM vaccine. The hypothesis of the study was that the vaccine as a supplementary therapy for CMM would increase the survival of dogs with MM.
Materials and methods: Eight dogs with an average age of 9.2 years old were treated with a xenogeneic human tyrosinase vaccine against CMM, after surgical removal of the tumor and radiation therapy. The vaccine was administered 4 times biweekly, and a vaccination boost was suggested to be given 6 months after the last vaccination. After therapy, the dogs visited the surgical oncology policlinic at Utrecht according to a preset protocol. 
Results: One dog had recurrence of the tumor, one dog had metastasis and one dog developed a recurrence and a metastasis.The mean survival time for these eight dogs was 109 days. There was no increase in survival time observed, compared to the survival times described in literature with conventional treatment. One WHO stage 3 dog had a survival time of 132 days end died at the end of the study. 
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Canine Malignant Melanoma MM (CMM) is a neoplasm of melanocytic cells of dogs. It is a relatively common neoplasm, accounting for 4 to 7 % of all neoplasms, 7 % of all malignant neoplasms and 9 to 20 % of all skin tumors in dogs (Smith et al., 2002; Modiano et al., 1999; Hrabeta et al., 2007). A benign neoplasm of melanocytes is called a melanocytoma (or melanoma). 
The sites where CMMs appear, are the oral cavity, lip, skin, digits and the eye. The most frequently affected site is the oral cavity, making CMM the most common oral neoplasm. Oral melanomas are pigmented, but amelanotic oral melanomas are also reported. The site for oral melanomas is the gingiva, buccal or labial mucosa, hard or soft palate and the tongue.
Malignant melanoma of the digits is the second most common tumor of the digits. Most other cutaneous melanomas are benign.
CMM is a rapidly growing, invasive and potentially metastatic tumor. Especially, oral melanomas, and to a lesser degree digital melanomas, often recur after surgical excision and radio- or chemotherapy. They may invade bone as well as soft tissue. Oral melanomas tend to metastasize in 70 to 90% of all cases, while melanomas of the digits do so in 32 to 40% and melanomas of the skin in 15% (North et al., 2010; Manley et al., 2011).	
Dogs that are more susceptible to the development of oral melanoma are dogs with heavily pigmented oral mucosa like the Golden Retriever, Scottish Terrier, German Shepherd, the Boxer, Cocker Spaniel, Poodles and the Dachshunds (North et al., 2010; Bergman et al., 2007; Ramos-Vara et al., 2000). The Irish setter, Chihuahua, Golden Retriever and the Cocker Spaniel have greater risk in developing melanoma of the lip (Smith et al., 2002). Dogs at greater risk of melanocytic tumors of the digits and nailbeds are the Irish and Gordon Setters and the Golden Retriever (North et al., 2010).  
Dogs predisposed for developing cutaneous melanomas are dogs of small breeds with heavily pigmented skin like the Miniature Schnauzer, Standard Schnauzer, Dobermann Pinscher, Cocker Spaniel and Scottish terrier (Bergman et al., 2007; Manley et al., 2011; North et al., 2010). Metastasis of canine intraocular melanocytic neoplasms is rarely reported. One study reports intraocular melanocytic neoplasms in mixed breeds, Cocker Spaniel, Labrador Retriever, German Shepherd, Golden Retriever and the Schnauzer. The German Shepherd seems to be predisposed. 77 % of the intraocular canine research population had an intraocular melanocytoma and 23 % had an intraocular melanoma. 25 % of the dogs in the melanocytoma group had died after one year, while 25 % of the dogs in the melanoma group had died after 0,69 years after ocular surgery(Giuliano et al., 1999).
Sex has not been demonstrated to be a prognostic factor for CMM. Earlier studies report that male dogs have a higher frequency of melanoma than females. Several more recent studies have not reported any significant sex difference in terms of survival (Hrabčta et al., 2007;Smedley et al., 2011). CMM is most often diagnosed in dogs older than 10 years; one study reported a mean age of 11.6 years (Smedley et al., 2011; Smith et al., 2002).
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Pathogenesis
There is not much known about the pathogenesis of melanomas in dogs. There is an indication that other factors, than those known from human melanomas, may play a key role in developing canine melanocytic tumors. Melanocytes are dendritic cells, which have their origin in neuroectodermal melanoblastic cells. These cells have migrated during the embryogenesis to the epidermis, dermis and other sites. Melanocytes are situated within the basal layer of the epidermis, spread between basal keratinocytes. The melanocytes normally do not touch other cells, but form junctions with some keratinocytes surrounding them. The matter that gives the skin its colour, melanine, is not stored in a normal melanocyt. It is packaged in melanosomes and transferred through their dendritic extensions to keratinocytes. So normal melanocytes are nonpigmented and spread throughout the epidermis, in contrary to neoplastic melanocytes which are pigmented and grouped.
In humans, the cause of neoplastic tranformation of melanocytes is mainly by UVA and UVB solar radiation. This is based on the relation between melanoma epidemiology and sunlight exposure and skin type. Most animals, in this case dogs, have mainly haired skin.
Because of this haired skin, the influence of sunlight to the development of melanocytic tumors is minimal. Genetic susceptibility in breeds and family, resulting in more spontaneous mutations in DNA of cells, is more likely to play a key role in the development of melanocytic tumors (Smith et al., 2002).
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Classification
The World Health Organization (WHO) has developed a scheme for classifying oral melanomas in dogs. The classification of a tumor is based on: de anatomic site of the tumor, the tumor size and the tumor stage. These variables give an impression of the prognosis of CMM.

The anatomic site of the tumor gives an indication for local invasiveness and metastatic potential.
Melanomas of the haired skin are often benign, while oral melanomas and melanomas of the digit and footpad are often malignant.
The tumor size and stage can be subdivided in categories:  
-	Category 1: tumor ≤ 2 cm diameter 
-	Category 2: tumor diameter 2 to 4 cm
-	Category 3: tumor ≥ 4 cm diameter 
-	Category 4: distant metastasis. Distant metastasis has a higher grade than lymph node metastasis

Negative prognostic histological findings are: not been able to surgically remove all tumor tissue, incomplete surgical margins, caudal mandibula and rostral maxilla (worse prognosis), tumor mitotic index >3 and bone invasion or lysis.
Histological findings are not included in the criteria for the World Health Organization classification scheme for oral melanomas.

According to these criteria, the stage in which an oral melanoma can be categorized is:
-	Stage 1; tumor ≤ 2 centimeter in diameter, without lymph node involvement and no proven metastasis
-	Stage 2; tumor 2-4 centimer in diameter, without lymph node involvement and no proven metastasis
-	Stage 3; tumor ≥ 4 centimeter in diameter, with or without lymph node involvement and has no proven metastasis or any tumor size with lymph node metastasis
-	Stage 4; proven metastasis, independent of tumor size or lymph node involvement

The classification system for canine non-oral melanoma is less well developed yet. Tumor size and stage are: 2
-	Stage 1: tumor < 2 centimeter in diameter and superficial
-	Stage 2: tumor 2-5 centimeter in diameter and minimum invasion
-	Stage 3: tumor > 5 centimeter or invading the subcutis 
-	Stage 4: tumor invading fascia and bone (Bergman, 2007).





Dogs with masses on the digits, foot pads or in the oral cavity are suspects for CMM.
The difference between benign and malignant melanocytic tumors is unclear macroscopically.  

Melanocytic tumors are usually solitary, well circumscribed, round shaped, solid, brown to black but sometimes non-pigmented, hairless, sometimes ulcerated, peduncle or wart like shape and 0.5 to 10 cm in diameter. An oral melanoma causes signs of oral discomfort, loss of appetite and difficulty in swallowing (Medleau et al., 2001).  

In case of a malignant melanocytic neoplasm, cytology on a tumor biopsy will show round, oval, star-like or spindle shaped cells with cytoplasm containing granules of dark pigment. Through cytology it is sometimes hard to recognize malignant melanomas because some melanomas tend to be non-pigmented and melanoma cells often show pleiomorphism: a great variability in size and shape of neoplastic cells and nuclei. Dermatohistopathology will give outcome. Histopathology can show accumulation of neoplastic melanocytes, which may have a spindle like shape, epithelial or round cell look.
Cells are arranged together in a group and can have a variable degree of pigmentation. Malignant melanomas have a more invasiveness appearance, poor differentiation, cellular pleomorphism and a high mitotic index.

Cytology shows a reactive lymph node in 53-74 % of the cases. A reactive lymph node doesn’t necessarily have to be a metastasis. When the regional lymph nodes are of normal size on palpation, they could still be positive for metastasis (North et al., 2010).






Sometimes it is hard to diagnose amelanotic melanocytic neoplasms, due to a lack of pigmentation and a high cellular pleomorphism. Because melanocytes can differentiate into spindloid or epitheloid cells during embryonic development, melanocytic neoplasms can look similar to carcinomas, soft tissue carcinomas, sarcomas and round cell neoplasms like lymphomas. These types of cancer differ in prognosis and treatment in dogs.
In this situation, immunohistochemistry could provide an outcome for diagnosing canine melanocytic neoplasms. Antibodies such as Melan-A, PNL2, TRP1 and TRP2 seem to be highly sensitive and 100 % specific for the detection of amelanotic melanocytic neoplasms according to several studies. S100 and MiTF markers are highly sensitive, but less specific
(Smedley et al., 2001; Medleau et al., 2001).

The next step in the diagnostic procedure is to determine whether the melanoma has metastasized to the regional lymph nodes or to the internal organs. Fine needle lymph node aspiration with cytology could show a metastasis or a reactive lymph node with some melanocytes.
Depending on the site of the tumor, a X-ray or CT scan of the thorax or an ultrasound of the abdomen will be inconclusive for distant metastasis. In 57 % of the oral melanoma patients there is radiographic evidence of bone involvement and pulmonary metastasis is seen in 14 % of cases. The treatment of CMM consists of surgical removal of the tumor, in combination with radio- or chemotherapy (Bergman, 2007; Smedley et al., 2001; North et al., 2010).
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Prognosis
Dogs diagnosed with malignant melanoma have a poor prognosis. In spite of the surgical removal of the tumor with additional radio- or chemotherapy, most dogs die of distant metastasis and not from local recurrence. Most locations reported for metastatic disease are the regional lymph nodes, brain, kidney, heart, liver and lungs. While radiation therapy could stretch the survival time a little, melanomas seem to be very chemotherapy resistant.
Recent studies have reported a median survival time of 12 up to 14 months for dogs with oral melanoma stage 1, after surgical removal and radio- or chemotherapy. Dogs with stage 2 melanoma have a median survival time of less than 5 months after surgical intervention, and dogs with stage 3 or 4 melanoma have a survival time of 2 to 3 months (Bergman, 2007; Alexander et al., 2006; Bergman et al., 2003).

A study evaluating the treatment of oral melanoma with surgical removal and radiation therapy, reported a median survival range from 5 to 8 months. Surgically removed oral melanomas with a partial maxilla- or mandibulectomy have lower recurrence rates than is the case in local excision. In dogs with stage 1, 2 or 3 oral melanoma the recurrence rates were 48 % after hemimaxillectomy and 38 % after partial maxillectomy with 1 cm surgical margins
This study reports reports a median survival time for an oral melanoma of 147 days and a median time to recurrence or metastasis of 78 days (Spangler et al., 2006).

Another study focused on 39 dogs with oral melanoma, with most dogs diagnosed as a stage 1 melanoma. These dogs were treated with hypofractionated radiation therapy and chemotherapy, after surgery. This study reports recurrence in 15 % of the dogs, with a median time to local recurrence of 139 days. 51 % of the dogs developed a disease caused by distant metastasis, with a median time of 311 days. The median survival time of all dogs was 363 days, with a one-year overal survival rate of 45 %. After surgical treatment alone, the median metastasis free interval has been reported to be 1.25 to 6.5 months, and the one-year survival rate was 27% (Freeman et al., 2003).
 













Cutaneous melanocytic neoplasms tend to be malignant in 39 to 50% of the cases. Eventually, 12% behave malignant. The mean time to recurrence of metastasis after surgical removal reported, is 270 days. Mean survival time is 17 to 24 months. 10 % of the dogs with a mitotix index of <2 died within two years because of the tumor related disease after surgical excision and 73 % of the dogs with a mitotix index of >3 died within two years(Spanger et al., 2006; Bostock, 1979; Mulligan, 1961). Bostock reported that 45% of dogs with malignant skin melanomas died within 1 year, whereas 8% of dogs with benign skin melanomas died from their disease (Bergman et al., 2007).























Table 1: prognosis of Malignant Oral Melanoma with conventional treatment

	(Bergman et al., 2003;2007)	(Spangler et al., 2006)	(Freeman et al., 2003)
Survival times	Stage 1; 12-14 monthsStage 2; < 5 monthsStage 3 or 4; 2-3 months	Overall 5-8 months, median survival time of 147 days.	
Recurrence rates		Recurrence rates of 48 and 38% after hemi and partial maxillectomy	15 %
Metastasis rates		78 days	51 %
Recurrence free interval		78 days	139 days
Metastasis free interval			
One year survival rate			27 %

Table 2: prognosis of Cutaneous Melanoma with conventional treatment

	(Spangler et al., 2006)	(Bostock, 1979; Mulligan, 1961).	(Bergman et al., 2007)
Survival times		17-24 months	
Malignancy rate	39 to 50%, eventually 12%		
Recurrence free interval	270 days		
One year survival rate		90% with MI <2	
Two year survival rate		23% with MI >3	
Table 3: prognosis of Digital Melanoma with conventional treatment

	(Manley et al., 2011)	(Begman et al., 2007)
Survival times	12 months	~12 months
One year survival rate	42-57%	42-57%
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DNA vaccine for CMM
CMM has a very metastatic potential. After aggressive therapies like wide surgival removal, radiation and chemo therapy, metastatic systemic disease is a common event. CMM also responds poorly to chemo therapy. Therefore, it is necessary to develop new strategies against CMM (Manley et al., 2011; Bergman et al., 2003; Bergman et al., 2007).

The last decade there has been a revolution in cancer immunotherapy. 
Despite adequate treatment of CMM, consisting of tumor excision and radiation therapy, there is still a high chance of distant metastasis. These potential metastasis need to be treated immediately. Today there are no effective treatment methods to prevent or eliminate these metastasis. In these cases, immunotherapy could be a potential therapy for melanomas when administered as a DNA vaccine. The vaccine will trigger the immune system to fight these micro-metastasis.

A DNA vaccine consists of a bacterial plasmid with an antigen and an active promoter built in. The antigen that is built in the plasmid is an antigen of the human tyrosinase family. Tyrosinase is a glycoprotein of melanocytes, that converts the chemical reaction of tyrosine into melanine. This human tyrosinase is also called xenogeneic, because it is a foreign enzyme for the dog’s immune system. Human tyrosinase resembles canine tyrosinase with 87.5 % of the amino acid composition homology. Because of the tissue specific expression of the glycoprotein tyrosinase, tyrosinase is a useful target for immunotherapy against CMM.
The vaccine will be introduced into the muscle of a dog through a trans-dermal injection.
Once inside the animal, the muscle cells take up the plasmid with the human tyrosinase antigen and expresses it on their own cells. The muscle cells are now seen by the dog’s immune system as foreign due to the human tyrosinase antigen, triggering antigen presenting cells like dendritic cells to take up the antigen. These antigen presenting cells will induce antibodies against human tyrosinase and a cytotoxic T-cell response. The increase in antibody amounts suggests an overcoming of the canine immune tolerance and a cross reaction of these antibodies with canine tyrosinase. The induced antibodies and cytotoxic T-cells will attack the canine melanocytes, leading to tumor regression. The plasmid also contains immunostimulatory DNA sequences. These sequences function as a potential adjuvant in the immune response against melanocytic tumor cells.
It is yet unclear how tyrosinase, as an intracellular melanosomal glycoprotein, can be recognized and targeted by antibodies in intact tumor cells. 





Figure 3; Method of antigen presentation that will induce an immune response after DNA vaccination. DNA can directly transfect dendritic cells, which can migrate to draining lymph nodes to activate T-cells. Dendritic cells can also be activated when they take up antigen from dying myocytes or keratinocytes. They can activate CD8+ and CD4+ cells in the lymph node via Class 1 or Class 2 MHC-complexes  (Srinivasan et al., 2004). 


DNA vaccination only seems to work optimal when metastasis is limited to micro-metastasis. Therefore it will always be administered after local tumor control and radio- or chemotherapy. 
The advantages of DNA vaccination are the relatively inexpensive production of DNA, the simple production in large amounts and the minimal reported toxic side effects. The only side effect sometimes seen is a mild pain reaction to the injection. There is one report of a dog that developed depigmentation of the skin after vaccination. 
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The first study to the survival of dogs with CMM treated with xenogeneic human tyrosinase, reports a median survival time of 389 days. There was one report of a dog with a stage 4 tumor with a survival time of 588 days, who was still alive at the end of the study. 16
Another study reports a median survival time of 33 out of 170 dogs in the category of stage 2 and 3 CMM, of 569 days. At the end of this study, 25 out of the 33 dogs were still alive  (Bergman, 2007; Bergman et al., 2003).

A study on the effectiveness of a xenogeneic DNA vaccine against CMM of the digits reports a mean survival time after the first vaccination of 351 days, with 50 % of the dogs alive after 1 year and 36 % alive after 2 and 3 years. The mean survival time from the date of diagnoses was 476 days, with 63 % of the dogs alive after 1 year and 32 % alive after 2 and 3 years. Dogs with stage 1 or 2 were reported to have longer survival times than those with stage 3 or 4 CMM. The median survival time in this study for dogs with stage 1 CMM was more than 952 days, stage 2 more than 1093 days, stage 3 321 days and stage 4 76 days (Manley et al., 2011).
2. Bergman, P. J. Canine Oral Melanoma. Clin. Tech. Small Anim. Pract. 22, 55-60 (2007). 
6. Manley, C. A. et al. Xenogeneic Murine Tyrosinase DNA Vaccine for Malignant Melanoma of the Digit of Dogs. J. Vet. Intern. Med. 25, 94-99 (2011). 
16. Bergman, P. J. et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: A phase I trial. Clinical Cancer Research 9, 1284-1290 (2003). 
Aim of the study
The aim of this study was to investigate the effectiveness of the DNA vaccine against CMM. The research question is: will the xenogeneic human tyrosinase vaccine against CMM significantly increase the survival time of dogs?
Because the canine melanoma vaccine is still in an experimental stage, much more research and evaluation must be done. 
This study was performed at the University of Utrecht, Faculty of Veterinary Medicine, Department of Clinical Sciences of Companion Animals, Surgical Oncology.
Statistical variables including the time of recurrence, the time of metastasis, the time to disease, death of a dog caused by CMM or another disease and the survival time of dogs diagnosed for CMM treated with the DNA vaccine, were evaluated. 
Data from this study will be compared to data described in the literature of dogs that also received the vaccine and to data of dogs which received conservative treatment and no vaccine.









From the period of February 2011 until June 2011, eight dogs diagnosed with CMM were treated with the melanoma vaccine. Before the administration of the vaccine, the tumor was surgically removed and radiation therapy was performed on the tumor area and regional lymph nodes. After the administration of the vaccine, contact with the owners of the patients was made regularly. The patients visited the policlinic of surgical oncology for a check-up at 1, 3 and 6 months after vaccination. During the 3 and 6 months control, the patients underwent a chest radiographic analysis and CT scan, respectively. After 6 months, the patients were scheduled to received another vaccination round after consultation with the specialist.
During these contact moments, the state of health of these patients was monitored. Tumor recurrence, metastasis, disease and survival times were collected to determine the effectiveness of the DNA vaccine. 

Animals
This study comprised eight dogs between the age of 6 to 13 years old, with an average of 9.2 years, and a mean body weight of  25.2 kg varying from 14.8 to 41.0 kg. 
The majority of the dogs included in this study were males; six of the eight dogs.
The study population consisted of a Shiba Inu, Labrador retriever, Leonberger, German shepherd, Nova Scotia duck tolling retriever, border collie, and two beagles.
Dogs that were allowed in the study were all found positive for CMM by cytological and histological examination. Three dogs were diagnosed according to the ‘World Health Organization tumor malignancy scale as a stage 1 melanoma, two as a stage 2 melanoma, three as a stage 3 melanoma and one as a stage 4 melanoma. Six dogs had an oral melanoma, while one dog had a cutaneous melanocytoma and one dog had a digital melanoma.





Brumby	ShibaInu	26-5-2005	Male	15,1 kg	Oralmelanamo	Stage 2	Cclear 
Borka	LabradorRetriever	1-4-2001	Male	39,8 kg	Oral melanoma	Stage 1	Clear
Dino	Beagle	15-9-2002	Male	14,8 kg	Oral melanoma	Stage 2	Not clear
Bobby	Beagle	23-6-1998	Male	15,5 kg	Oral melanoma	Stage 3	Not clear
Luna	Leonberger	4-10-2002	Female	41,0 kg	Oral melanoma	Stage 1	Not clear
Joyce	Border Collie	18-9-1998	Female	18,2 kg	Oral melanoma	Stage 4	Not clear
Woody	Nova ScotiaDuck TollingRetriever	14-1-2003	Male	22,7 kg	CutaneousMelanocytoma	Stage 3	Clear
Blues	German Shepherd	10-3-2004	Male	34,5 kg	Digitalmelanoma	Stage 3	Clear

Regular treatment
To determine the state of health of the patients, a complete physical examination, a blood screening test, a complete blood count and urinalysis were performed. During the physical examination, the size of the tumor was determined. The blood screening test consisted out of a serum chemistry profile.

A biopsy of the regional lymph nodes was taken for cytological examination and a CT scan of the skull and thorax or thorax and abdomen and the lymph nodes regions were taken to see whether or not metastases were present.
This data, including the size of the tumor, determined the tumor stage based on the World Health Organization tumor-node-metastasis guidelines for CMM.	

The next step in the treatment was to surgically remove the tumor and metastatic lymph nodes. Surgical removal of the tumor was performed in five dogs by the owners’ own veterinarian and in three dogs at the Department of Clinical Sciences of Companion Animals in Utrecht. During surgery, the surgeon or veterinarian attempted to remove all the tumor tissue with wide margins. Tumor removal with wide margins was not always established, according to pathological and histological investigation postoperatively on the tumor tissue. Finally all tumor tissue and metastasis material were stored and frozen for RNA analysis.

Seven of the eight patients received radiation therapy after surgery. Radiation therapy started within 7 to 10 days after surgery and consisted out of 6 fractions with a fraction dose of 6 Gy.
These radiation fractions were given twice a week, for up to 3 weeks. The operation area was radiated with 3 cm lateral margins and minimal 85 % of de 6 Gy was treated 3 cm into the depth. Next to the operation area, the regional lymph node area was preventively treated to minimize the risk of possible metastasis.

DNA vaccination
The DNA vaccine was produced in America by a genetic laboratory using cDNA coded with human tyrosinase which was subcloned into a bacterial expression vector. This expression vector is also known as pING and contains a cytomegalovirus promoter and kanamycin resistance selection marker. Further more the vaccine was completed with an endogenous adjuvant, in the shape of unmethylated CpG nucleotide sequences. This adjuvant would activate antigen presenting cells through Toll like receptor 9.
The melanoma vaccine was administered 4 times to the patients, with an interval of 2 weeks between each vaccination. The vaccine was given in a dose of 500 ug through a transdermal system under high pressure, in the musculus semitendinosus or semimembranosus. 
It wasn’t necessary to sedate the patients before the vaccination, but the first 2 vaccinations were combined with 2 radiation sessions. Only authorized veterinarians administered the vaccine while the animal caretakers or the research project student fixated the patients during vaccination  (Bergman et al., 2003).


Figure 4; Bacterial pING human tyrosinase plasmid, used for human tyrosinase 




After the last vaccination, the patients had to come on a regular base to the policlinic of oncology for a check-up. Some patients of owners who lived in Belgium or Germany underwent these check-ups at their own veterinarian because of travel issues.
The first check up was one month after the last vaccination and consisted of a history and complete physical examination of the patient. Extra attention was made to the removed tumor area for local recurrence and to the regional lymph nodes.
The second control was three months after the last vaccination. Again a full physical examination was done and radiographs were taken to screen the thorax for possible metastasis. The third control was six months after the last vaccination, again a physical examination and this time a CT-scan were performed. In consultation with the specialist, the patients could receive a booster vaccine in absence of metastasis on CT-scan. The following controls will take place in a similar fashion after the 2nd therapy.
Between each control, contact by telephone with the owners was made on a regular basis to monitor the health of the patients.


Analysis of tumor progression
The aim of this study was to investigate the effectiveness of the canine melanoma vaccine.
To achieve this goal, some variables were defined to analyze the progression of the tumor after surgical excision and radiotherapy. Also the dogs were monitored for any side effects.

The tumor stage based on the node-tumor-metastasis classification of the World Health Organization determined the tumor malignancy for each patient. The date of the first clinical symptoms and the date of diagnosis were reported from the reference of the owners´ veterinarian. The date of the first treatment was reported. This is the date on which the patients received their first vaccination. Also the date of the last contact was reported.

The first variable for tumor progression analysis is the RFI date or Recurrence Free Interval. This is the date on which recurrence of the tumor was determined or the number of days free from recurrence of the tumor at the site where the primary tumor was removed.
The second variable is the MFI date or Metastasis Free Interval. This is the date on which metastasis of the tumor was determined or the number of days free from metastasis to the regional lymph nodes or to the skull, thorax or abdomen.
The third variable is the DFI date or Disease Free Interval. This is the date on which the first clinical symptoms are seen or the number of days free from disease due to melanoma disease.
The fourth variable is the ST or survival time. This is the date on which the patients died because of melanoma disease, or because the study ended. It can also be defined as the number of days the patient stayed alive after the first vaccination.
We used a censor on the variables DFI, RFI and MFI. The censor defined as ‘0’ meant that the event did not occur and censor ‘1’ meant that the event did occur. Information about these variables was collected through a survey among the owners of the patients or their veterinarians and through follow-ups at the surgical oncology policlinic.

Statistics
To determine the effectiveness of the melanoma vaccine, the results of the variables were compared to those of other literature studies in which dogs with CMM were treated with the melanoma vaccine. The mean survival time of dogs with CMM treated with the vaccine was calculated by the average days of survival, according to the data collected.

Kaplan-Meier analysis were made for the estimation of the mean RFI, MFI and DFI times, including Kaplan-Meier survival plots with the use of SPSS.
The Kaplan-Meier is a statistical method to estimate the survival function from lifetime data.
Because all the dogs survived at the end of this study, its not possible to make a Kaplan-Meier survival analysis. So for this reason, Kaplan-Meier RFI, MFI and DFI were made.
Variables like weight, tumor size and age were evaluated for their effect on RFI, MFI or DFI times by the Cox’s proportional hazards analysis with SPSS. The Cox proportional hazards regression model is a method to investigate the effect on survival, or in this case RFI, MFI or DFI, of several variables at the same time. The dependent variable in a Cox regression analysis is called the hazard, the probability of dying at a particular time, conditional on the animal surviving up to that time.
Variables like ST, RFI, MFI and DFI were compared to those described in other literature.









Two dogs had recurrence of the tumor, and two dogs developed metastasis. One stage 3 dog developed metastasis to the lungs and the brain after 87 days and also had a recurrence of tumor tissue in the region of the removed left mandibular lymph node. This dog died 132 days after treatment. One stage 2 dog developed a cutaneous melanoma in the groin after 70 days, it is unclear if this was another primary tumor or a metastases, because no other metastases were found or developed after resection. No major side effects were observed related to the vaccinations. Dogs reacted to the click of the device and rarely vocalised during the injection.

Table 4; n=8





















The mean survival time in days according to the ST date (Table 5) for all eight dogs after the first vaccination is 109 days. The mean survival time in days for stage 1 melanoma is 150 days, for stage 2 melanoma 157 days and for stage 3 and 4 103 days.

The mean survival time in days from the date of diagnosis for all eight dogs is 158 days. The mean survival time in days from the date of diagnosis for stage 1 melanoma is 185 days, for stage 2 melanoma 195 days and for stage 3 and 4 138 days.

Kaplan​-Meier RFI, MFI and DFI analyses were made with SPSS (Figure 3).

The estimated mean time in which the patients had recurrence of the tumor, also called the RFI date, was 170 days with a standard error (SE) of 20.3 and a 95 % confidence interval (CI) of 130.5 – 209.8 days.


Figure 5: Kaplan-Meier RFI plot for dogs with CMM treated with the melanoma vaccine.













Figure 6: Kaplan-Meier MFI plot for dogs with CMM treated with the melanoma vaccine.





















Figure 7: Kaplan-Meier DFI plot for dogs with CMM treated with the melanoma vaccine.













The aim of the study was to investigate the effectiveness of the melanoma vaccine.
Conventional treatment of CMM shows a mean survival time of 5 to 8 months. Dogs with stage 1 CMM have a mean survival time of 12 to 14 months, stage 2 less than 5 months and stage 3 and 4 have a mean survival time of 2 to 3 months.

The results of this study show a mean survival time of 109 days after the first vaccination, and 158 days after the day of diagnosis. Three dogs with stage 1 melanoma had a mean survival time of 150 days after the first vaccination, two dogs with stage 2 melanoma 157 days and three dogs with stage 3 or 4 melanoma 103 days.
So for the stage 1, 2, 3 and 4 melanoma in this study, there is not an increase in survival time in comparison to conventional treatment. Although, one dog with a stage 3 melanoma had a survival time of 132 days, which compares favorably to the 60-90 days reported .
There were two dogs with recurrence of the tumor. One of these dogs (Bobby) also developed a metastasis of the primary tumor to the brain and lungs. One dog with a stage 2 oral melanoma (Brumby) also developed a possible metastasis (cutaneous) to the groin.  

According to the Kaplan-Meier RFI estimation by SPSS, the mean time to recurrence of the tumor was 170 days. The MFI estimation was 167 days and the mean estimated DFI time was 152 days. One study reports a median time of 78 days to recurrence or metastasis of oral melanoma. So in this study population, the mean RFI date is far above the 78 days. One stage 3 dog (Bobby) died because of distant metastatic disease at the end of this study. Borka had a liposarcoma after three months that was surgically removed and Brumby and Woody had metastasis and recurrence to the distant and local skin area after three and two months (Bergman, 2007; Spangler  et al., 2006; Bergman et al., 2003;; Freeman et al., 2003;).

According to earlier studies, the xenogeneic human tyrosinase DNA vaccination against CMM seems to have a positive effect. This is based on antitumor responses, low levels of toxicity observed, an increase in survival time and an increase in tyrosinase specific antibodies and cytotoxic T-cells. The first study of Bergman in 2003 evaluating the survival of dogs with oral CMM after DNA vaccination with xenogeneic human tyrosinase shows a median survival time of 389 days. In this study there was even one stage 4 dog alive at the end of the study after 588 and another stage 4 dog with a survival time of 421 days. Two stage 3 dogs had survival times of 496 and 501 days and were euthanatized because of unrelated melanoma disease.

A study in 2011 to the survival of dogs with melanoma of the digits after xenogeneic murine tyrosinase DNA vaccination show a mean survival time of 351 days, comparable to the study of Bergman. The median survival time in this study for dogs with stage 1 CMM was more than 952 days, stage 2 more than 1093 days, stage 3 321 days and stage 4 76 days (Bergman et al., 2006; Manley et al., 2011).
2. Bergman, P. J. Canine Oral Melanoma. Clin. Tech. Small Anim. Pract. 22, 55-60 (2007). 
6. Manley, C. A. et al. Xenogeneic Murine Tyrosinase DNA Vaccine for Malignant Melanoma of the Digit of Dogs. J. Vet. Intern. Med. 25, 94-99 (2011). 
11. Freeman, K. P., Hahn, K. A., Harris, F. D. & King, G. K. Treatment of Dogs with Oral Melanoma by Hypofractionated Radiation Therapy and Platinum-Based Chemotherapy (1987-1997). Journal of Veterinary Internal Medicine 17, 96-101 (2003). 
14. Spangler, W. L. & Kass, P. H. The histologic and epidemiologic bases for prognostic considerations in canine melanocytic neoplasia. Vet. Pathol. 43, 136-149 (2006). 
16. Bergman, P. J. et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: A phase I trial. Clinical Cancer Research 9, 1284-1290 (2003). 

Other studies report a correlation for the induction of specific antibodies to an intracellular tumor antigen and positive clinical outcome in some patients. On the contrary, other immune cells like CD8+ and cytotoxic T-cells must play a key role tot the overall anti tumor response against CMM. This because there are also positive outcomes in some patients with no detectable antibody response after vaccination (Bergman et al., 2003; Liao et al., 2006).

16. Bergman, P. J. et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: A phase I trial. Clinical Cancer Research 9, 1284-1290 (2003). 
19. Liao, J. C. et al. Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. Cancer immunity [electronic resource] : a journal of the Academy of Cancer Immunology. 6, 8 (2006). 

Considerations
The mean survival time described in earlier studies was 389 days after the first vaccination. 
In February the first dogs received the melanoma vaccine, and some had their first vaccination in May. Because this study ended per the first of September, there was unfortunately to little time to follow all the dogs and near the mean survival time of 389 days. 
Most dogs didn’t have an increase in survival time, according to the expected survival times for each CMM stage that received conventional treatment. One stage 3 dog did.
The difference in survival times compared to the study of Bergman could be explained by the small study population of eight dogs and the short evaluation time of the study.




















In this study eight dogs diagnosed with CMM received a xenogeneic human tyrosinase vaccine after surgical removal of the tumor and radiation therapy.
The vaccine was administered in a total of four times biweekly, and a vaccination boost needs to be given 6 months after the last vaccination. The dogs regularly visited the surgical oncology receiving for a check-up. The first control was one month, the second three months and the third control was six months after the last vaccination. During the second control a radiographic x-ray or CT-scan was made from the thorax or abdomen, and during the third control a CT-scan was made.

The mean survival time for the eight dogs was 109 days. This implies no increase in survival time compared to conventional treatment, described in literature of dogs diagnosed with CMM. Although, one stage 3 dog had a survival time of 132 days. Two dogs had recurrence of the tumor; one of these two dogs also developed metastasis to the regional lymph nodes, lungs and the brain. Another stage 2 dog developed a cutaneous metastasis to the groin. The mean estimated RFI, MFI and DFI times were 170, 176 and 152 days according to the Kaplan-Meier analysis by SPSS. No significant influence of weight, tumor size or age were seen on the RFI, MFI and DFI times.
The first study to the survival time of dogs treated with a xenogeneic DNA vaccine show a mean survival time of 389 days. Many other studies for the last decade show the same survival times. These studies have proven positive effects of the xenogeneic DNA vaccine against CMM, next to surgical removal and radiation therapy. The results of these studies for the xenogeneic DNA vaccine show a safe use, leading to the development of antityrosinase antibodies, a potential therapeutic use and further evaluation and research must be done.
So the first outcome of this study, supported with earlier studies show a positive effect of the melanoma vaccine withouy negative side effects. The study population and the research time must be enlarged to at least 30 dogs and one year, in order to be compared to the 389 days of survival time that are represented in literature.
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